Results from the Phase 3 Clinical Study of Novel Anti-PD-1 mAb Serplulimab for the First-line Treatment of ESCC Released at 2023 ASCO Annual Meeting

Release Time：2023-06-02 Author： Source: Pageviews：

Previous：515 Fosun Family Day Sets Off Consumption Boom With Cumulative Sales of Nearly RMB10 Billion Next：515 Fosun Family Day Joins Hands with Global Ecosystem to Bring You What You Want

Latest News

2023-09-28

Fosun Showcases LANVIN, Oriental Haute Couture and Yuyuan Original at WDCC 2023
2023-09-26

Fosun International’s FTSE Russell ESG Rating Upgraded to 3.8, Maintains Inclusion in FTSE4Good Index Series
2023-09-26

STORE OF THE DAY AUTUMN 2023: Tom Tailor Launches New Store Design in Vienna
2023-09-26

Fosun International has been awarded the “ESG Benchmark Awards”
2023-09-25

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC